A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-08-29
Adverse events
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2022-09-22 (study day 12); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-08 (study day 28); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 41); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 44); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-27 (study day 47); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-27 (study day 47); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 52); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 70); relationship: N
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 70); relationship: N
Data queries
No data queries.